medigraphic.com
ISSN 1729-519X (Print)

2016, Number 3

<< Back Next >>

Revista Habanera de Ciencias Médicas 2016; 15 (3)

Effectiveness and safety use of botulinal toxin compared to others medicinal alternatives in patients with focal dystonia

Mesa BY, Hernández RTE, Parada BY

Language: Spanish
References: 29
Page: 348-362
PDF size: 420.47 Kb.


ABSTRACT

Introduction: medical treatment for focal dystonia is initially indicated as a treatment prior to application of botulinal toxin (BTx), but due to, generally does not respond satisfactorily to the treatment; it is necessary to reach this final stage with the application of botulinal toxin.
Objective: To determine the effectiveness and safety use of botulinal toxin in patients with focal dystonia who have received other treatment lines.
Material and Methods: A randomized, double-blind study in a 35 patient’s cohort with dystonia, administrating botulinal toxin type A (Botox) to 19 patients and the other 16 continued medical treatment for 4 months which previously were treated with other therapeutic alternatives for more than 3 years without a satisfactory response.
Results: There was a predominance in women with a 74.3%; the most common focal dystonia was blepharospasm; the drug more used were benzodiazepines; there was a significant reduction in scale scores after 3 months; the onset of action was 4 days after shot, loss of effect at 11 weeks; patients and researchers clinical impression; regarding the treatment, was of slight to marked improvement; as well as tolerableness evaluation as very good for 85%.
Conclusion: The application effectiveness of botulinal toxin in reducing involuntary spasms in patients with dystonia is greater than other medicinal therapeutic alternatives with good safety and tolerability, which confirmed this treatment as a first-line treatment in these entities.


REFERENCES

  1. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. European Federation of Neurological Science (EFNS) guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011; 18(1):5-18.

  2. Orsini M, Leite MA, Chung TM, Bocca W, de Souza JA, de Souza OG, et al. BotulinumNeurotoxin Type A in Neurology: Update. Neurol Int. 2015; 7(2):5886.

  3. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin nerves A into phrenic. FEBS Lett. 2006; 580(8):2011-4.

  4. Bakshi E, Hartstein ME. Compositional differences among commercially available botulinum toxin type A. Curr Opin Ophthalmol. 2011; 22(5):407-12.

  5. Dressler D. Botulinum toxin for treatment of dystonia. European Journal of Neurology. 2010; 17(Suppl): 88-96.

  6. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidencebased review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 1; 67:94-114.

  7. Centers for Disease Control and Prevention (CDC) et al. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep. 2010; 59(10):299.

  8. Ravenni R, De Grandis D, Mazza A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci. 2013; 34(7):1043-8.

  9. Ostrem JL, Marks WJ Jr, Volz MM, Heath SL, Starr PA. Pallidal deep brain stimulation in patients with cranial cervical dystonia (Meige syndrome). Mov Disord. 2007; 22(13):1885–91.

  10. Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015; 107(Pt A):77-84.

  11. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013; 28(7):863-73.

  12. Cesaretti C, Grippo A, Vettori A, Atzori T, Baldini C, Falsini C. Botulinum toxin for the upper limb after stroke: Comparison between incobotulinumtoxin A, botulinum toxin drug free of complexing proteins, and conventional botulinum toxin formulation. A preliminary study. Clinical Neurophysiology. 2013; 124(11):199-200.

  13. Kwakkel G, Meskers CG. Botulinum toxin A for upper limb spasticity. Lancet Neurol. 2015; 14(10):969-71.

  14. Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, et al. International Abobotulinumtoxin A Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015; 14(10):992-1001.

  15. Barnes TG, Zafrani Z, Abdelrazeq AS. Fissurectomy Combined with High-Dose Botulinum Toxin Is a Safe and Effective Treatment for Chronic Anal Fissure and a Promising Alternative to Surgical Sphincterotomy. Dis Colom Rectum. 2015; 58(10):967-73.

  16. MacLachlan LS, Rovner ES. New treatments for incontinence. Adv Chronic Kidney Dis. 2015; 22(4):279-88.

  17. Schaefer SM, Gottschalk CH, Jabbari B. Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins Basel. 2015; 7(7):2615-28.

  18. Mor N, Tang C, Blitzer A. Temporomandibular Myofacial Pain Treated with Botulinum Toxin Injection. Toxins Basel. 2015; 7(8):2791-800.

  19. Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2015; 33(4):291-8.

  20. Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013; 5(4):821-40.

  21. Huang XF, Wang KY, Liang ZH, Du RR, Zhou LN. Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China. Eur Neurol. 2015; 73(5- 6):337-41.

  22. Han Y, Stevens AL, Dashtipour K, Hauser RA, Mari Z. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol. 2016 Feb 25.

  23. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Larynqoscope. 2015; 125(8):1751-7.

  24. Sorgun MH, Yilmaz R, Akin YA, Mercan FN, Akbostanci MC. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. J Clin Neurosci. 2015; 22(8):1319-25.

  25. Scaglione F. Conversion Ratio between Botox(®), Dysport(®), and Xeomin(®) in Clinical Practice. Toxins (Basel). 2016; 8(3).

  26. Kukreja R, Chang TW, Cai S, Lindo P, Riding S, Zhou Y, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon. 2009; 53(6):616-24.

  27. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008; 23(10):1353-60.

  28. Tomczak KK, Rosman NP. Torticollis. J Child Neurol. 2013; 28(3):365-78.

  29. Camargo CH, Cattai L, Teive HA. Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment. Toxins Basel. 2015; 7(6):2321-35.




2020     |     www.medigraphic.com